Prof Terpos speaks to ecancer about the real-world evidence of the use of carfilzomib among multiple myeloma patients with at least one prior therapy across 10 European countries and Israel. This study was presented at ASH 2020.
He initially explains what this study was about and says that this study aimed to understand carfilzomib usage, effectiveness and safety in patients with relapsed or refractory multiple myeloma (RRMM) in real-life.
It describes the results of an interim analysis by carfilzomib-based regimens from a large prospective observational study. He then talks about the methodology and key results of this study.
Prof Terpos says that the benefit-risk profile of KRd and Kd in the real-world was consistent with clinical trial results from ASPIRE and ENDEAVOR, respectively. Both KRd and Kd achieved deeper responses in earlier lines of therapy, emphasising the importance of optimising MM therapies.
In the end, he talks about how this study can impact the future treatment of multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.